The blog

The science in plain English

Plain-English explainers on GLP-1 nutrition, muscle preservation, side effects and the newest research on Ozempic, Wegovy, Mounjaro and Zepbound. No hype - just what the evidence says.

Research An experimental injection pen labelled NLY01 beside a brain-and-spine icon, illustrating that the one trial testing a GLP-1 drug for multiple sclerosis uses an experimental drug, not Ozempic or Wegovy, and has no results until about 2030

Can Ozempic or Wegovy help multiple sclerosis?

No. No GLP-1 drug is proven to treat MS. The one dedicated trial tests an experimental drug, NLY01 - not Ozempic or Wegovy - with no results until about 2030.

Oct 23, 2026·8 min
Research A dose dial turning a GLP-1 injection pen from the 2.4 mg setting up to 7.2 mg, illustrating how Wegovy HD adds about 3 percentage points more weight loss but nearly four times as many altered skin sensations

What is Wegovy HD, and is the higher dose worth it?

The 7.2 mg dose took off about 3 points more weight than 2.4 mg in STEP UP - at the cost of nearly four times as many altered skin sensations.

Oct 21, 2026·8 min
Research A wall calendar with a single day circled each month beside a GLP-1 injection pen, illustrating that no once-a-month GLP-1 shot is approved yet and that berobenatide is still in phase 3 testing for monthly dosing

Is there a once-a-month GLP-1 injection yet?

Not yet. No monthly GLP-1 shot is approved anywhere. Berobenatide (Pfizer) is in phase 3 for monthly dosing, with results expected in 2028.

Oct 20, 2026·6 min
Research An editorial illustration of a survodutide injection pen marked with two hormone symbols, beside pill-shaped badges reading 9.8% weight loss, GLP-1 plus glucagon and not approved yet, showing that a 2026 phase 3 trial tested the new dual agonist in people with type 2 diabetes but no trial has compared it to Ozempic

What is survodutide, and is it better than Ozempic?

A new GLP-1 and glucagon dual agonist. Adults with type 2 diabetes lost 9.8% of body weight in its first phase 3 trial - but no study has compared it to Ozempic.

Oct 19, 2026·7 min
Research An editorial illustration of a birth-control pill pack and a GLP-1 injection pen balanced on a scale, beside pill-shaped badges reading 1.4 to 2.1x more likely, link not cause and weight is the clue, showing that a 2026 Danish study of 22,694 women tied hormonal contraception to later starting semaglutide without proving the pill caused it

Did my birth control make me need Ozempic?

A 2026 Danish study of 22,694 women found contraception users were 1.4 to 2.1 times more likely to later start semaglutide. Why that is a link, not a cause.

Oct 14, 2026·7 min
Research An editorial illustration of a DNA double helix beside a GLP-1 injection pen with pill-shaped badges reading plus 0.76 kg per gene copy, tirzepatide-only nausea gene and no test yet, showing that a 2026 Nature study found genes nudge how well Ozempic and Mounjaro work but cannot yet predict an individual response

Can a genetic test predict if Ozempic will work?

A 2026 Nature study of 27,885 people found genes that nudge GLP-1 weight loss and nausea. The effects are tiny, the data is self-reported, and no test can yet predict your response.

Oct 13, 2026·8 min
Research An editorial illustration of a friendly GLP-1 injection pen beside a cross-section of a throat and voice box, with pill-shaped badges reading cough most common, lump-in-throat feeling and likely reflux not damage, showing that a 2026 study linked Ozempic and similar drugs to a small rise in throat and voice symptoms most likely caused by reflux

Does Ozempic affect your voice or throat?

A 2026 study of 617,296 GLP-1 users found a small but real rise in cough, throat and voice symptoms. The likely cause is treatable reflux, not vocal-cord damage.

Oct 12, 2026·8 min
Research An editorial illustration of a positive pregnancy test and a GLP-1 injection pen beside pill-shaped badges reading 2.1 million pregnancies, no clear rise and not for use in pregnancy, showing that the largest 2026 studies found no clearly detectable increase in major risks from conceiving while on Ozempic or Mounjaro

Is Ozempic safe if you get pregnant on it?

The largest 2026 studies, including one of 2.1 million pregnancies, found no clear rise in major risks from conceiving while on a GLP-1 drug. Reassuring about an accident, still not a reason to use it in pregnancy.

Oct 9, 2026·8 min
Research An editorial illustration of a GLP-1 injection pen next to a small dose marker and pill-shaped badges reading 25 to 50 percent, less nausea and no trial yet, showing that microdosing Ozempic or Mounjaro means a smaller off-label dose with little evidence that it works and real safety risks

Does microdosing Ozempic or Mounjaro work, and is it safe?

A fraction of the usual dose, taken off-label to ease nausea and cut cost. High-quality evidence is essentially absent, early reports are mixed, and the real risk is often the unregulated product, not the small dose.

Oct 8, 2026·7 min
Research An editorial illustration of a skin cross-section with collagen fibers and a fibroblast cell beside a GLP-1 pen and a magnifying glass, with small badges for receptors, oxidative stress and no human trial, showing that whether GLP-1 drugs age skin directly is still an open research question in 2026

Do GLP-1 drugs age skin directly?

Researchers are studying whether GLP-1 drugs age skin on their own, beyond weight loss. Skin cells carry GLP-1 receptors, but as of 2026 the idea rests on lab reasoning and computer models, not a human trial.

Oct 5, 2026·8 min
Research An illustration of a face losing volume in the cheeks and temples beside a GLP-1 pen, with small badges for fat loss, slower weight loss and collagen, showing that Ozempic face is caused mainly by rapid whole-body fat loss reaching the face rather than a skin-specific drug effect

What causes Ozempic face?

Mainly the rapid weight loss, not a skin-specific drug effect. Fat leaves the face as total body fat falls, and two reviews tie it to facial volume loss and sagging. Whether GLP-1 drugs age skin directly is proposed but unproven.

Oct 2, 2026·8 min
Research An illustration of a person yawning beside a GLP-1 pen, a downward energy line and small icons for iron, water and sleep, showing how Ozempic and Mounjaro cause only a small rise in daytime sleepiness while improving sleep apnea and how most tiredness traces to fixable causes

Does Ozempic or Mounjaro make you tired?

There is no single answer. A 2026 study of 118,993 users found only a small rise in daytime sleepiness, while these drugs strongly improve sleep apnea, a major cause of tiredness. Most fatigue traces to fixable causes like low iron, too little food or dehydration.

Sep 30, 2026·8 min
Research An illustration of a patch of calming psoriasis plaques on skin beside a downward-trending weight scale and a GLP-1 pen, showing how Ozempic and Mounjaro may ease psoriasis severity mostly through weight loss while a few people had paradoxical flares

Can Ozempic or Mounjaro help psoriasis?

Early evidence says yes. A 2026 review of 26 studies found semaglutide and liraglutide sharply cut psoriasis severity scores in small groups, mostly through weight loss. But a few people flared instead, no GLP-1 is approved for psoriasis, and no large trial has confirmed it.

Sep 29, 2026·8 min
Research An illustration of an ear with a highlighted eustachian tube beside a downward-trending weight scale and a GLP-1 pen, showing how Ozempic and Mounjaro were linked to better hearing in a 2026 diabetes study while rapid weight loss can cause a patulous eustachian tube that feels like blocked ears

Can Ozempic or Mounjaro affect your hearing?

No good evidence these drugs damage hearing, and a 2026 study even linked GLP-1 use to better thresholds in people with diabetes. But rapid weight loss can leave the eustachian tube abnormally open, causing blocked, echoey ears that feel like hearing loss and are usually manageable without stopping the drug.

Sep 28, 2026·8 min
Research An illustration of a healthy leg vein with smooth blood flow beside a downward-trending weight scale and a GLP-1 pen, showing how Ozempic and Mounjaro were linked to fewer DVT and pulmonary embolism clots in a 2026 study, most likely through weight loss

Does Ozempic or Mounjaro cause blood clots?

There is no evidence they cause clots. The largest 2026 study found fewer DVT and PE clots in high-risk vein patients on GLP-1 drugs, most likely through weight loss. But the finding is observational and population-specific, and haematologists still call the question unresolved.

Sep 25, 2026·8 min
Research An illustration of a downward-trending weight scale beside a bladder icon and a GLP-1 pen, showing how Ozempic and Mounjaro may reduce stress incontinence and bladder leaks indirectly through weight loss

Can Ozempic or Mounjaro help bladder leaks?

Weight loss reduces stress incontinence and GLP-1 drugs cause weight loss, so fewer bladder leaks are plausible. But the benefit is indirect, the 50-70% figure is bariatric surgery not a drug effect, no GLP-1 is approved for incontinence, and the first dedicated trial reports in 2028.

Sep 23, 2026·8 min
Research An illustration of inflamed skin nodules beside a GLP-1 injection pen and a quality-of-life chart trending up, showing how Ozempic and Mounjaro may calm hidradenitis suppurativa lesions mostly through weight loss

Can Ozempic or Mounjaro help hidradenitis suppurativa?

Pooled observational studies suggest GLP-1 drugs may calm HS lesions and improve quality of life, but reviews disagree on whether it is the weight loss or a direct anti-inflammatory effect. No GLP-1 is approved for HS, and the first randomized trial has not begun.

Sep 22, 2026·9 min
Research An illustration of a big-toe joint and a blood-test vial beside a GLP-1 injection pen, showing how Ozempic and Mounjaro can lower the uric-acid number while not being proven to prevent gout attacks

Does Ozempic or Mounjaro help gout?

These drugs usually lower your uric-acid number, mostly from weight loss, but the largest real-world study did not show GLP-1 drugs preventing gout, while SGLT2 diabetes drugs did. Uric acid is not gout, and no GLP-1 is approved for it.

Sep 21, 2026·8 min
Research An illustration of a brain and an eye beside a GLP-1 injection pen, showing how Ozempic and other GLP-1 drugs may lower the raised pressure of idiopathic intracranial hypertension and protect vision

Can Ozempic help idiopathic intracranial hypertension?

2026 reviews link GLP-1 drugs like Ozempic to less papilloedema, fewer headaches and less surgery in IIH (pseudotumor cerebri), and a small trial hints at a direct pressure-lowering effect. No GLP-1 is approved for IIH, and the evidence is early. What it shows, and what it does not.

Sep 18, 2026·8 min
Research An illustration of a brain beside a GLP-1 injection pen, showing whether Ozempic and other GLP-1 drugs are safe for people with epilepsy and whether they raise or lower the risk of seizures

Is Ozempic safe if you have epilepsy?

A 2026 study of 610 adults with epilepsy found no link between starting a GLP-1 drug and worse seizure control, and it still drove weight loss. A separate study even tied semaglutide to a lower risk of a first seizure. What the evidence shows, and what it does not.

Sep 17, 2026·7 min
Research A GLP-1 injection pen beside an operating-room sign and a clear plastic cup of liquid, illustrating whether to stop Ozempic, Wegovy or Mounjaro before surgery or a colonoscopy and how anaesthesia teams now individualise the timing

Do I stop Ozempic before surgery or a colonoscopy?

GLP-1 drugs leave more food in the stomach before anaesthesia, but the best evidence does not show they raise actual aspiration. Do not stop on your own - tell your surgical and anaesthesia team early, because guidance now individualises the timing.

Sep 16, 2026·8 min
Research A GLP-1 injection pen and a tirzepatide pen beside a ranking chart and a blood-glucose meter, illustrating a 2026 meta-analysis that ranked tirzepatide and semaglutide first and second among all options for preventing type 2 diabetes in people with prediabetes

Can Ozempic or Mounjaro prevent type 2 diabetes?

A 2026 meta-analysis of 378 trials ranked GLP-1 drugs and tirzepatide first and second among every option for preventing type 2 diabetes in prediabetes, just ahead of metformin plus lifestyle. What the ranking proves, and what it does not.

Sep 14, 2026·8 min
Research A semaglutide injection pen beside a brain icon and a hospital symbol, illustrating a nationwide study linking semaglutide, but not liraglutide or dulaglutide, to fewer psychiatric hospitalisations in people who have both bipolar disorder and diabetes or obesity

Can Ozempic help bipolar disorder?

A nationwide Swedish study linked semaglutide, but not liraglutide or dulaglutide, to a 21% lower risk of psychiatric hospitalisation in people with bipolar disorder plus diabetes or obesity. What the observational finding does and does not show.

Sep 11, 2026·8 min
Research Illustration of a diverse group of people standing beside a GLP-1 injection pen and a bar chart comparing weight-loss results, showing that GLP-1 drugs like Ozempic and Mounjaro produce broadly similar percentage weight loss across ethnicities but that trials are too small to prove equal results

Do GLP-1 drugs work as well for every ethnicity?

A 2026 meta-analysis found nearly identical percentage weight loss in Asian and non-Asian adults, while one clinic reported Hispanic patients lost less. What the data can and cannot prove about GLP-1 drugs across ethnicities.

Sep 10, 2026·8 min
Research Illustration of a laboratory mouse beside a GLP-1 injection pen and an hourglass, with a dashed arrow pointing to a human silhouette marked with a question mark, showing that a Nature study extended lifespan in mice on semaglutide but that the result is not proven in humans

Does the Ozempic mouse lifespan study apply to humans?

A 2026 Nature study extended lifespan in aged female mice on semaglutide and mimicked calorie restriction. No human trial shows any GLP-1 drug extends human lifespan. What the mouse evidence proves, and what it does not.

Sep 8, 2026·9 min
Research Illustration of a human digestive tract beside a GLP-1 injection pen and a small balance scale weighing benefit against risk, showing that GLP-1 drugs like Ozempic and Mounjaro are linked to fewer IBD-related surgeries but are not proven to reduce Crohn's disease or ulcerative colitis flares

Does Ozempic help or worsen Crohn's and colitis?

Some data link GLP-1 drugs to fewer IBD surgeries, but the best-designed 2026 study found no change in flares. None is approved to treat IBD. The honest, two-sided read.

Sep 8, 2026·9 min
Research Illustration of a nerve pathway splitting into two directions, one calm and one frayed, beside a GLP-1 injection pen and a small vitamin badge, showing that in type 2 diabetes GLP-1 drugs are linked to less nerve pain while rapid weight loss can rarely cause a nutritional nerve injury

Does Ozempic cause nerve pain, or help it?

In type 2 diabetes, GLP-1 drugs are linked to less nerve pain. A rarer nerve injury can follow rapid weight loss through vitamin deficiency. What the 2026 evidence shows on both sides.

Sep 4, 2026·9 min
Research Illustration of two small medicine vials labelled cagrilintide and semaglutide flowing together into a single once-weekly CagriSema injection pen, beside a downward-trending blood-sugar line and a small 0.16 points badge, showing how Novo Nordisk's CagriSema combines an amylin drug with the GLP-1 in Ozempic and slightly out-lowered HbA1c in the 2026 REIMAGINE type 2 diabetes trials

Is CagriSema better than Ozempic for type 2 diabetes?

In the 2026 REIMAGINE 2 head-to-head, Novo Nordisk's CagriSema edged semaglutide 2.4 mg by 0.16 HbA1c points. Statistically superior, clinically modest. What the pivotal diabetes trials showed.

Sep 3, 2026·9 min
Research Illustrated GLP-1 injection pen beside a warning triangle and three labelled situation icons for type 1 diabetes, an SGLT2 inhibitor pill and unsupervised weight-loss use, showing that ketoacidosis on Ozempic, Wegovy and Mounjaro is rare but clusters around specific circumstances

Can Ozempic or tirzepatide cause ketoacidosis?

Ketoacidosis on GLP-1 drugs is rare. A 2026 review of 25 type 1 diabetes studies found no clear rise; the danger clusters around insulin deficiency, SGLT2 co-use, and unsupervised cosmetic use.

Sep 2, 2026·9 min
Research Illustration of a Mounjaro injection pen and a rival GLP-1 pen balanced on a scale beside a heart, with badges reading noninferior and superiority missed, showing that the 2026 SURPASS-CVOT trial found tirzepatide matched but did not beat dulaglutide for cardiovascular events in type 2 diabetes

Does Mounjaro protect your heart better than other GLP-1s?

The FDA approved Mounjaro for heart protection in type 2 diabetes on August 28, 2026, but SURPASS-CVOT tested it against another heart-protective GLP-1 and it matched without beating. What noninferiority really means.

Aug 31, 2026·8 min
Research Illustration of a person walking farther along a path beside a GLP-1 injection pen, with small badges for peripheral artery disease and leg pain, showing that semaglutide in Ozempic improved walking distance and is linked to fewer amputations in people with PAD and type 2 diabetes

Can Ozempic help peripheral artery disease?

In the 2026 STRIDE trial, semaglutide helped people with PAD and diabetes walk about 13% farther, and a large cohort links GLP-1 drugs to fewer amputations. What that proves, and what it does not.

Aug 29, 2026·8 min
Research Illustration of a healthy pair of lungs breathing easily beside a GLP-1 injection pen, with small badges for asthma and COPD, showing that Ozempic, Wegovy and Mounjaro do not appear to harm breathing and are linked to fewer respiratory flare-ups

Is Ozempic safe if you have asthma or COPD?

A 2026 review of 123 studies found no rise in respiratory side effects, and large cohorts link GLP-1 drugs to fewer asthma and COPD flare-ups. The evidence, and its limits.

Aug 28, 2026·8 min
Research Illustrated digestive tract with a rushing water droplet and a rotten-egg gas bubble beside a GLP-1 injection pen, with a water glass and a low-fat meal nearby, showing why Ozempic, Wegovy, Mounjaro and Zepbound cause diarrhea and sulfur burps and what helps

Why does Ozempic give you diarrhea and sulfur burps?

The same drug that constipates one person gives another loose stools and rotten-egg burps. The mechanism, the four-label rates, and what helps.

Aug 26, 2026·8 min
Research Illustrated pancreas beside a GLP-1 injection pen with a shield and a warning triangle, showing that a 2026 meta-analysis found no significant pancreatitis increase on Ozempic, Wegovy, Mounjaro and Zepbound while acute pancreatitis stays a labelled warning

Does Ozempic cause pancreatitis?

A 2026 meta-analysis of 52 studies found no significant rise in pancreatitis, but the labels still warn about it. What the numbers actually say.

Aug 24, 2026·8 min
Research Illustrated digestive tract slowed to a crawl beside a GLP-1 injection pen, with a water glass, fibre-rich foods and a walking figure nearby, showing why Ozempic, Wegovy, Mounjaro and Zepbound cause constipation and what helps relieve it

Why does Ozempic make you constipated?

The same slowed gut that curbs appetite hardens your stool. Rates run from about 3% on Ozempic to 24% on Wegovy, plus what actually helps.

Aug 23, 2026·8 min
Research Illustrated knee joint with a highlighted cartilage layer beside a GLP-1 injection pen, one panel showing a human trial marked 407 people and less pain and a second panel marked mice only for cartilage repair, showing that semaglutide reduced knee-arthritis pain in people but that cartilage regrowth has so far only been demonstrated in animals

Can Ozempic help arthritis and grow new cartilage?

Semaglutide cut knee pain in the 407-person STEP 9 trial, mostly via weight loss. The cartilage-growth claim, though, is still a mouse study.

Aug 19, 2026·9 min
Research Illustrated pancreas beside a GLP-1 injection pen and a stack of research papers marked 60 studies and 4.9 million people, showing that the largest 2026 review found no increased risk of pancreatic cancer for people on Ozempic, Wegovy, Mounjaro or Zepbound, and that acute pancreatitis, not cancer, is the warning on the label

Does Ozempic cause pancreatic cancer?

The largest review, 60 studies and 4.9 million people, found no increased risk. The label warns about pancreatitis, not cancer, and here is the difference.

Aug 18, 2026·8 min
Research Illustrated heart and a blood-pressure cuff beside a GLP-1 injection pen, one gauge arrow pointing down and one pointing up, showing that Ozempic and other GLP-1 drugs lower systolic blood pressure by about 2 to 5 mm Hg while raising resting heart rate by about 2 to 5 beats per minute

Does Ozempic lower blood pressure and raise heart rate?

Blood pressure drifts down about 2 to 5 mm Hg, resting pulse drifts up about 2 to 5 bpm. Both small, and why you should never cut a BP pill on your own.

Aug 5, 2026·8 min
Research Four labelled pill bottles for Rybelsus, the Ozempic pill, the Wegovy pill and Foundayo beside a fifth greyed-out bottle marked elecoglipron in trials, mapping the GLP-1 pills approved in the US in 2026 and how the diabetes, weight-loss and investigational pills differ

How many GLP-1 pills are there now?

Four pills are approved, and two are the same drug. A plain map of the diabetes pills, the weight-loss pills, and the one coming next.

Aug 4, 2026·8 min
Research Illustrated knee joint beside a GLP-1 injection pen and a stack of research papers marked 43 trials and 100,488 people, showing that large randomized studies found no increase in joint pain, arthritis or gout for people on Ozempic, Wegovy, Mounjaro or Zepbound

Does Ozempic cause joint pain?

43 trials, 100,488 people, no signal. Joint pain is on none of the four US labels, and for knees the evidence leans toward benefit.

Aug 3, 2026·9 min
Research Illustrated open mouth and a dental mirror beside a GLP-1 injection pen and a checklist of the four US drug labels, showing that taste change and belching are listed on all four while dry mouth appears on only one, which is why patients on Ozempic, Wegovy, Mounjaro and Zepbound should tell their dentist

Should I tell my dentist I'm on Ozempic?

Ozempic mouth is a patient word, not a label word. Dry mouth appears on exactly one of the four US labels.

Aug 1, 2026·9 min
Research Illustrated thyroid gland in a human neck beside a GLP-1 injection pen and a timeline contrasting 2.8 years of trial follow-up with a 20-year cancer latency, illustrating that trials of Ozempic, Wegovy, Mounjaro and Zepbound recorded about 6 thyroid cancers per 10,000 patients against 4 per 10,000 on control but ran too briefly to settle the question

Does Ozempic cause thyroid cancer?

15 trials, 84,237 people, no significant increase. The authors still rate their own evidence very low certainty.

Jul 31, 2026·9 min
Research Illustrated menstrual cycle calendar and ovary beside a GLP-1 injection pen and a pack of oral contraceptive pills, showing that the only tier-1 fertility evidence for Ozempic is a single 80-woman trial with a 35% pregnancy rate and that the oral contraceptive warning applies to tirzepatide rather than semaglutide

Does Ozempic make you more fertile?

The whole "Ozempic babies" evidence base is one 80-woman trial. The birth-control warning is on tirzepatide, not semaglutide.

Jul 30, 2026·9 min
Research Human eye with the optic nerve highlighted beside a GLP-1 injection pen and two arrows pointing in opposite directions, illustrating why NAION is listed as a very rare semaglutide side effect at about one extra case per 10,000 person-years while a 28-study meta-analysis of Ozempic and Wegovy found no increased risk

Can Ozempic damage your eyes?

Europe calls NAION a very rare side effect of semaglutide. The biggest review found no risk, until it removed one study.

Jul 29, 2026·9 min
Research GLP-1 injection pen beside a small plate, a water glass and a paused dose-escalation dial, illustrating how nausea affects 44% of Wegovy users and how slower titration, smaller lower-fat meals and hydration help people stay on Ozempic, Wegovy and Zepbound

How do I deal with Ozempic nausea without quitting?

Nausea hits 44% of Wegovy users versus 16% on placebo. A 2026 clinical guide sets out what to change before you consider stopping.

Jul 28, 2026·8 min
Research GLP-1 semaglutide capsule beside a dinner plate and a rising hunger line, illustrating the Penn trial finding that people on Ozempic and Wegovy still eat 24% to 30% fewer calories at 60 weeks even after felt hunger returns

Does Ozempic stop working when the hunger comes back?

A 60-week Penn trial found semaglutide users still ate 24% to 30% fewer calories at week 60, even after the hunger advantage disappeared.

Jul 27, 2026·8 min
Research Foundayo orforglipron oral GLP-1 pill tablet beside a downward weight-loss arrow, illustrating the first FDA-approved non-peptide GLP-1 receptor agonist for chronic weight management

How much weight can you lose on Foundayo?

Foundayo (orforglipron), the first oral non-peptide GLP-1 pill, was FDA-approved April 1, 2026. Its pivotal trial showed up to 11.1% average weight loss at 72 weeks.

Jul 21, 2026·7 min
Research GLP-1 semaglutide injection pen beside a brain and scale icon, illustrating the CAMH trial testing whether semaglutide helps people with schizophrenia and antipsychotic-induced weight gain who did not respond to metformin

Can semaglutide help people with schizophrenia lose weight?

A CAMH trial is testing weekly semaglutide in 92 adults with schizophrenia who did not respond to metformin, tracking psychiatric symptoms alongside weight.

Jul 17, 2026·8 min
Research GLP-1 medication capsule with red beadlets beside a downward weight-loss arrow, illustrating retatrutide, the triple-agonist obesity drug in Eli Lilly's completed Phase 3 TRIUMPH-1 trial that produced up to 24% weight loss in phase 2

Retatrutide and TRIUMPH-1: what we know so far

Eli Lilly's triple-agonist hit 24.2% weight loss at 48 weeks in Phase 2. Its Phase 3 trial TRIUMPH-1 has finished, but no results are posted yet.

Jul 16, 2026·8 min
Research GLP-1 medication capsule with red beadlets beside a heart icon, illustrating Amgen's MARITIME-HF trial testing MariTide (maridebart cafraglutide) for heart failure with preserved ejection fraction and obesity

Can MariTide treat heart failure and obesity?

Amgen's Phase 3 MARITIME-HF trial tests MariTide, a once-monthly GLP-1 agonist and GIP antagonist, in ~5,056 people with obesity and heart failure. Recruiting now - no results yet.

Jul 11, 2026·7 min
Research GLP-1 medication capsule with red beadlets beside a pink ribbon icon, illustrating the FITWISE trial (NCT06518837) testing weekly tirzepatide for weight loss in adults with early-stage HR+/HER2- breast cancer

Can tirzepatide help breast cancer survivors lose weight?

Rutgers' FITWISE trial gives 40 breast cancer survivors with obesity weekly tirzepatide, tracking weight loss and 3-year recurrence risk. Recruiting now - no results yet.

Jul 9, 2026·6 min
Research GLP-1 medication capsule with red beadlets beside a heart icon, illustrating the NCT06980623 study comparing tirzepatide and semaglutide in patients with type 2 diabetes and heart failure with preserved ejection fraction

Tirzepatide vs semaglutide for HFpEF: what's being studied

A 26,000-patient claims-data study compares tirzepatide and semaglutide in type 2 diabetes with HFpEF. No results yet.

Jul 4, 2026·6 min
Research GLP-1 medication capsule with red beadlets beside an insulin pen, illustrating the SURPASS-T1D-2 trial testing weekly tirzepatide for adults with type 1 diabetes and obesity

Can tirzepatide help people with type 1 diabetes and obesity?

Eli Lilly's SURPASS-T1D-2 trial tests weekly tirzepatide vs. placebo in adults with type 1 diabetes. No results yet.

Jul 3, 2026·6 min
Research GLP-1 medication capsule with red beadlets beside a bone and muscle icon, illustrating the Wake Forest GLOW pilot trial testing whether tirzepatide plus protein counseling preserves lean mass and bone density in older adults

Does tirzepatide protect muscle and bone in older adults?

A Wake Forest pilot trial is giving 40 adults over 65 weekly tirzepatide plus protein counseling for 9 months. No results yet.

Jul 2, 2026·6 min
Research GLP-1 medication capsule beside a DNA double helix strand, illustrating the Zhejiang University trial testing whether semaglutide or tirzepatide slow epigenetic aging measured by DNA methylation testing

Can GLP-1 drugs slow biological aging?

A 66-person trial in China is testing whether semaglutide or tirzepatide slow epigenetic aging more than metformin. Recruiting now - no results yet.

Jun 30, 2026·6 min
Research Surgical scalpel and a GLP-1 medication capsule side by side, illustrating the Cleveland Clinic trial comparing bariatric surgery against semaglutide and tirzepatide for weight loss in adults with obesity

Bariatric surgery vs. semaglutide vs. tirzepatide

A Cleveland Clinic trial of 125 adults is running the first head-to-head comparison of bariatric surgery against semaglutide and tirzepatide. Underway now - no results yet.

Jun 29, 2026·7 min
Research GLP-1 medication capsule alongside a muscle diagram, illustrating the LEAN-PRO GLP-1 trial testing whether a high-protein diet preserves muscle mass in 130 adults with obesity during GLP-1 receptor agonist treatment

Can a high-protein diet stop GLP-1 muscle loss?

A new randomized trial of 130 adults in Greece is testing whether high dietary protein preserves more muscle than standard counseling during GLP-1 treatment. Recruiting now - no results yet.

Jun 26, 2026·6 min
Research GLP-1 medication capsule next to a heart diagram, illustrating the cardiovascular comparison between semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) - a 29% lower risk of major cardiovascular events with semaglutide in a real-world study of 21,250 patients

Semaglutide vs tirzepatide: which protects the heart more?

A 2026 real-world study of 21,250 patients found semaglutide cut major cardiovascular events by 22-29% versus tirzepatide - though the study was funded by semaglutide's maker.

Jun 25, 2026·7 min
Research GLP-1 supplement capsule alongside a muscle diagram, illustrating the lean mass loss that occurs with Ozempic, Wegovy, Mounjaro and Zepbound - roughly 24% of total weight lost is muscle, not fat

How much muscle do you lose on GLP-1 drugs?

A 2025 meta-analysis of 22 RCTs puts the number at 0.86 kg - about 24% of total weight lost. What it means for Ozempic, Wegovy, Mounjaro, and Zepbound users.

Jun 23, 2026·7 min
Research GLP-1 medication capsule next to a heart diagram illustrating the cardiovascular protection from semaglutide - 28% lower heart attack risk and 21% lower atrial fibrillation risk in a meta-analysis of 22,937 patients

Does semaglutide protect your heart? What 22,937 patients show

A 2025 meta-analysis of 10 RCTs found semaglutide cuts heart attack risk by 28%, atrial fibrillation risk by 21%, and angina risk by 23%. What Ozempic and Wegovy users need to know.

Jun 20, 2026·7 min
Research GLP-1 medication capsule with green beadlets illustrating the weight loss comparison between tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) - tirzepatide produces roughly 4 kg more weight loss on average across 142,000+ patients

Tirzepatide vs semaglutide: which drug loses more weight?

Two independent 2025 meta-analyses covering 142,000+ patients show tirzepatide (Mounjaro, Zepbound) outperforms semaglutide (Ozempic, Wegovy) by roughly 4 kg on average - a gap that grows at higher doses.

Jun 18, 2026·7 min
Research GLP-1 medication capsule next to a kidney diagram, illustrating the kidney protection from tirzepatide (Mounjaro) versus dulaglutide (Trulicity) - 23% lower risk of major kidney events in the SURPASS-CVOT trial of 13,000+ patients

Does tirzepatide protect the kidneys better than dulaglutide?

A pre-specified analysis of the SURPASS-CVOT trial in 13,299 patients found tirzepatide cut major kidney events by 23% versus dulaglutide - though Eli Lilly funded the trial and makes both drugs.

Jun 16, 2026·7 min
Join the waitlist

Be first to repair your nutritional gaps

Keep the weight loss. Fill the nutritional gap